全文获取类型
收费全文 | 12637篇 |
免费 | 587篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 356篇 |
儿科学 | 412篇 |
妇产科学 | 496篇 |
基础医学 | 1058篇 |
口腔科学 | 284篇 |
临床医学 | 1027篇 |
内科学 | 2608篇 |
皮肤病学 | 378篇 |
神经病学 | 882篇 |
特种医学 | 836篇 |
外国民族医学 | 4篇 |
外科学 | 2521篇 |
综合类 | 91篇 |
预防医学 | 753篇 |
眼科学 | 461篇 |
药学 | 560篇 |
中国医学 | 6篇 |
肿瘤学 | 502篇 |
出版年
2021年 | 61篇 |
2019年 | 66篇 |
2018年 | 91篇 |
2017年 | 68篇 |
2016年 | 98篇 |
2015年 | 578篇 |
2014年 | 690篇 |
2013年 | 729篇 |
2012年 | 843篇 |
2011年 | 819篇 |
2010年 | 735篇 |
2009年 | 698篇 |
2008年 | 822篇 |
2007年 | 769篇 |
2006年 | 697篇 |
2005年 | 656篇 |
2004年 | 485篇 |
2003年 | 292篇 |
2002年 | 212篇 |
2001年 | 237篇 |
2000年 | 209篇 |
1999年 | 200篇 |
1998年 | 91篇 |
1997年 | 89篇 |
1996年 | 92篇 |
1995年 | 68篇 |
1994年 | 90篇 |
1993年 | 78篇 |
1992年 | 149篇 |
1991年 | 168篇 |
1990年 | 170篇 |
1989年 | 182篇 |
1988年 | 152篇 |
1987年 | 123篇 |
1986年 | 128篇 |
1985年 | 112篇 |
1984年 | 109篇 |
1983年 | 86篇 |
1982年 | 66篇 |
1981年 | 66篇 |
1980年 | 63篇 |
1979年 | 96篇 |
1978年 | 76篇 |
1977年 | 65篇 |
1976年 | 56篇 |
1975年 | 54篇 |
1974年 | 61篇 |
1973年 | 69篇 |
1972年 | 72篇 |
1971年 | 56篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Well‐being,health and fitness of children who use wheelchairs: Feasibility study protocol to develop child‐centred ‘keep‐fit’ exercise interventions
下载免费PDF全文
![点击此处可从《Journal of advanced nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
2.
3.
4.
Chronic transplant dysfunction is a complex dynamic pathogenic process. Clinically, a decrease in glomerular filtration rate (GFR) becomes apparent leading to chronic renal insufficiency and dialysis or death from cardiovascular events. Chronic transplant dysfunction can develop into a chronic alIograft nephropathy (CAN) as a specific entity with dynamic progression. CAN includes a collection of immunologic and non-immunologic factors, rejection, ischemia time, donor and recipient characteristics and toxicity of calcineurin inhibitors. Despite improvements in immunosuppression, the long-range prognosis of renal allografts has not improved. Whether modern immunosuppressive concepts with reduction or avoidance of calcineurin inhibitors and a therapy based on antimetabolites, such as mycophenolate or mTOR-inhibitors could lead to a prolongation of transplant survival, remains to be seen. 相似文献
5.
6.
7.
8.
9.
S H Jacobson 《Scandinavian journal of urology and nephrology》1991,25(1):51-57
Fifty women with pyelonephritic renal scarring were prospectively followed for five years and the changes in renal function were related to blood pressure control, plasma renin activity, urinary albumin excretion and the incidence of urinary tract infections (UTI). Five patients (10%) developed end stage renal disease. All these patients had bilateral disease, proteinuria and anti-hypertensive treatment at presentation. The mean +/- SD glomerular filtration rate (GFR) of all patients with renal scarring was 74 +/- 27 ml/min x 1.73 m2 at presentation which was significantly lower than the GFR in 55 patients with a recent episode of acute pyelonephritis (p less than 0.001) and 10 healthy controls (p less than 0.001). GFR and age corrected GFR decreased significantly during follow-up (p less than 0.001) and p less than 0.02 respectively). The decrease in GFR was significantly higher in patients with bilateral scarring, in patients on blood pressure treatment and in patients with an episode of symptomatic UTI during follow-up. Eight patients (16%) had antihypertensive treatment at presentation and another 11 patients (26%), of whom 10 had bilateral scarring, developed hypertension (greater than 140/90 mmHg) during follow-up. Seventy-five per cent of all patients had symptomatic UTI and 40% had an episode of acute pyelonephritis during follow-up. In conclusion, patients with pyelonephritic scarring have a high incidence of UTI and are at high risk of developing renal failure and hypertension. It is essential that recurrent episodes of symptomatic UTI are treated promptly and that blood pressure is monitored carefully in these patients. 相似文献
10.
Five agents are currently approved for the treatment of chronic hepatitis B infection. This article will discuss the three agents for which the most extensive data are available; interferon (IFN), lamivudine, and adefovir, while the following article by Dr. Jules Dienstag will discuss the recently marketed agents, entecavir and peginterferon alfa-2a. The advantages of IFN are its finite duration of therapy (4–6 months), lack of emergence of resistance, and durability of response. On the negative side, response to IFN is less durable in patients with HBeAg-negative chronic hepatitis B virus (HBV). Also, use of IFN is limited by adverse effects and the mode of administration (daily to thrice-weekly subcutaneous injection). Lamivudine and adefovir are orally administered and have good tolerability and safety. Even in patients who experience a marked decrease in serum HBV DNA and loss of HBeAg, oral therapy needs to be continued for at least 6 months, to avoid the risk of reappearance of HBeAg and viremia. Rates of HBeAg seroconversion to anti-HBe-positivity increase with duration of lamivudine or adefovir therapy. The likelihood of development of resistance to lamivudine and associated viral breakthrough limits its long-term use. In patients with HBeAg-negative chronic hepatitis B, long-term therapy is usually required, as off-treatment relapse is common. The emergence of resistance to adefovir is delayed and infrequent, hence adefovir may be preferred in patients requiring long-term therapy. 相似文献